Company intelligence / Profile preview

Gyroscope Therapeutics

London, England, United Kingdompennmedicine.org ↗

Ownership: Private
Development stage: Phase 2

Overview

GT005 has shown encouraging results in Phase I/II trials for geographic atrophy secondary to AMD. The program has received Fast Track designation from the FDA. Positive data from the FOCUS trial support continued development; Phase II studies are ongoing in genetically defined patient populations.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (AAV2-based recombinant adeno-associated virus vectors)
Industry: Biotech

Drug pipeline

2 assets

GT005

Phase 2

Indications: Geographic atrophy secondary to age-related macular degeneration

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Gyroscope Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gyroscope Therapeutics.

Explore the full profile